Continued from page 1

Formerly barred student attends his prom

SHELTON — A Connecticut teen who was briefly barred from prom for his over-the-top invitation to his date finally got to go.

Shelton High School senior James Tate attended the prom Saturday, nearly a month after he was prohibited for posting his invitation to Sonali Rodrigues in 12-inch-high cardboard letters on the school wall.

School officials had said his invitation was a safety risk and suspended him for a day and barred him from the prom. Headmaster Beth Smith later reversed the decision, acknowledging the international attention the case received.

Dressed in a three-piece black tuxedo with a purple flower in his jacket pocket, Mr. Tate arrived at a pre-prom photo event followed by television cameras. Miss Rodrigues, dressed in a lavender prom dress, said he was funny and “pretty cute.”


Mom from ‘16 and Pregnant’ accused of drug crimes

ROME — A Georgia mother who appeared on an episode of MTV’s “16 and Pregnant” has been arrested on drug charges.

Authorities say 37-year-old April Michelle Purvis was arrested Sunday morning during a road check in Floyd County. Ms. Purvis is charged with felony possession of methamphetamine and misdemeanor possession of marijuana.

Ms. Purvis and her daughter, Whitney, were featured in the first season of the popular reality show about teenage pregnancy. A passenger in her car was charged with misdemeanor marijuana possession.


Two melanoma drugs show promise in studies

CHICAGO — Two new drugs using very different scientific approaches can extend survival among patients with the deadliest form of skin cancer, offering the first new hope for real progress in many years.

Advanced melanoma patients taking an experimental pill, vemurafenib, developed by Roche and Daiichi Sankyo were 63 percent less likely to die than patients given chemotherapy, according to a new trial presented Sunday at a meeting of the American Society of Clinical Oncology in Chicago.

Dr. Paul Chapman of Memorial Sloan-Kettering Cancer Center in New York and the study’s lead investigator called the results an “unprecedented level of difference” for patients with advanced melanoma, who typically survive just eight months on current treatments.

Story Continues →